

# Index

## A

Anion-radical superoxide ( $O_2^{\cdot-}$ ), 72  
Active targeting, 6  
Active targeting strategy, 51  
Adeno associated virus (AAV), 55  
Aerosol pyrolysis, 46  
Alkanolamines, 14  
Alternating current susceptibility, 66  
Aminopropyltriethoxysilane (APTS), 63  
Amorphous silica nanoparticles, 75  
Apo-transferrin protein, 66  
Aqueous routes, 13  
Atomic force microscope (AFM), 2

## B

Bioactive materials, 31  
Biocompatibility, 3  
Biocompatibilizer, 54  
Biodistribution Metabolism, Si, 59–65  
Bioglasses, 31–34  
Biological media, 19  
Biological system, 2  
Biomedical applications, 31, 32, 35  
Biomedical nanocomposites, 4  
Biomedicine, Si, 31–34  
    bioglasses, 31–34  
    mesoporous silica (*see* Mesoporous silica)  
    star gels, 31  
Biomolecules, 20  
Biosynthesis process, 16–17  
Bipolar anisotropic attraction, 19  
Bovine serum albumin (BSA) protein, 56

## C

California Institute of Technology  
(CALTECH), 1  
Cancer therapy, nanomedicine, 3  
Carbon nanotubes, 6  
CDSIR820, 82  
Chemical structure, silicon, 30  
Choline in silicon, 30  
Coat magnetic nanoparticles, 19  
Colloidal silica, 30  
Conventional drug therapy, 3  
Co-precipitation method, 14  
Core shell structure, 21  
Covalent linkage, 82  
Critical size, 10  
Crystalline silica, 72  
Cytotoxicity, 71–73, 75, 76

## D

Dendrimers, 5  
Diabetes, insulin in, 56  
Diet and silicon, 29–30  
Divalent metal transporter (DMT1), 66  
Diverse nanostructures, 3  
DOX, 82  
Doxorubicin, 10  
Doxorubicin, 54  
Doxorubicin (DOX), 82  
Doxorubicin target, 54  
Drug delivery, 31–33  
Drug delivery system, 9  
Drug delivery, nanostructures for, 5

Drug targeting, 3

#### Drugs

- gene and antibodies target and delivery, 55–56
- oncological diseases, 54–55
- other drugs and therapies, 56

#### E

- Electrochemical method, 17
- Endothelial growth factor (EGF), 33
- Epidoxorubicin, 22
- Excretion of Si, 59–65

#### F

- FDSIR820, 82
- Ferromagnetic material, 10
- Ferroportin, 66
- Fibroblast, 73
- Flow injection method, 17
- Folic acid, nanoparticles with, 7
- Free radicals, 72, 82

#### G

- Gelatin-silica nanovectors, 64
- Gene delivery system, 64
- Green fluorescent protein (GFP), 55

#### H

- Hemoglobin, 81
- Hemolysis assay, 74
- Hepatotoxic effects, 73
- High temperature thermal decomposition method, 14–15
- High-energy permanent magnets, 22
- Hybrid-carbon nanotubes, 6
- Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), 72
- Hydrolysis, 40, 41
- Hydrophilic drugs, 4
- Hydrophilic organic materials, 19
- Hydrothermal synthesis, 15
- Hydroxyl radical (OH<sup>•</sup>), 72

#### I

- Immediate drug delivery systems (IDDSs), 32
- Indocyanine Green (ICG), 82
- Ingepal<sup>®</sup>, 43
- Inorganic materials, 19
- Insulin, diabetes, 56
- Inverse core shell, 21

Iron (III) ions, 13

Iron alloys, 13

Iron oxide

- non-modified nanoparticles of, 19

Iron oxide based materials, 13

Iron oxide magnetic nanoparticles, 14

Iron oxide magnetic nanoparticles, toxicology of, 76–78

Iron oxide nanoparticles, 21, 66, 76, 82

#### J

Janus structure nanoparticles, 21

#### L

- Laser pyrolysis, 17
- Lipophilic drugs, 13
- Liposomes, 4, 5
  - current research on, 5
- Liquid crystal nanoparticles, 5

#### M

- Macrophages, 62
- Macrophages, 6
- MAG@CA, 41
- MAG@Si NPs, 52
- Maghemite, 13
- Magnetic albumin microspheres, 10
- Magnetic domains, 10
- Magnetic field directed targeting strategy, 51
- Magnetic hyperthermia, 23
- Magnetic materials, 10
  - types of, 11
- Magnetic nanoparticles, 7, 10
  - biodistribution about, 60
  - biodistribution of, 65
  - biomedical applications of, 10
  - coating agents for, 20
  - for drug delivery, 10
  - metabolism, 66
- Magnetic nanoparticles (MNPs)
  - silica as coating of, 52
- Magnetic nanoparticles, drug delivery devices, 14–17, 19, 20
  - description of coating, 17–21
    - biomolecules, 20
    - carbon, 20
    - inorganic materials, 20
    - organics, 19
    - polymers, 19
    - small molecules, 19
  - diverse coating agents, 20

- shape and morphology, 21
  - strategies to target by magnetism, 21–24
  - synthesis of magnetic cores, 12–17
    - biosynthesis, 16–17
    - co-precipitation method, 14
    - high temperature thermal decomposition method, 14–15
    - hydrothermal and solvothermal, 15
    - microemulsion, 15–16
    - microwave-assisted synthesis, 16
    - other methods, 17
    - shape, 17
    - sol–gel reactions and polyol method, 15
    - sonolysis/sonochemical method, 16
  - Magnetic silica nanoparticles, 67–68
    - future insights of biomedical applications, 83
    - toxicological studies in cell culture and in vivo of, 71–76
  - Magnetic solid silica nanoparticles, 71
  - Magnetically guided therapy, 23
  - Magnetic-carbon nanotubes, 6
  - Magnetic-silica nanoparticles
    - cytotoxic mechanism, 77
    - cytotoxic mechanisms, 77
  - Magnetism in biomedical applications, 10–12
  - Magnetite, 13
  - Magnetite nanoparticles, 76, 81
  - Magnetite nanoparticles, biodistribution and elimination of, 65–67
  - Magnetite@citric acid nanoparticles (MAG@CA), 40
  - Matrix dispersed structure, 21
  - Meso-2,3-dimercaptosuccinic acid (DMSA), 66
  - Mesoporous magnetic material
    - loaded drug, 53
  - Mesoporous silica, 31–34
    - advantages of, 33
    - benefits of, 32
    - IDDSs, 32
    - SDDSs, 32
    - stimuli-responsive controlled drug delivery systems, 32
    - targeted drug delivery systems, 33
  - Mesoporous silica nanoparticles, 52, 63
  - Metallic nanoparticles, 20
  - Methylene blue (MB), PS drug, 82
  - Microemulsion, 15–16
  - Microemulsion method, 42–44
  - Microwave-assisted synthesis method, 16
  - Miscellaneous methods, 45–46
  - Mixed oxide magnetic nanoparticles, 14
  - MNPs
    - dispersability, 45
    - iron from, 76
    - stability of, 45
  - MNPs@Si, 41
  - MNPs@Si-Doxo, 54
  - Mobile Crystalline Material (MCM-41), 32
  - Modified-solid silica nanoparticles, 64
  - Monodisperse macromolecules, 5
  - Monomeric silica, 30
  - Mononuclear phagocyte system (MPS), 62
  - Mouse peritoneal macrophages, 73
  - Mucopolysaccharides, 29
  - Mycophenolate mofetil, 55
  - Mycophenolic acid (MPA), 55
- ## N
- Nanocapsules, 4
  - Nanocarrier, 22
  - Nanocarriers, 23, 81
  - Nanocomposites, 3, 4
  - Nanocrystals, 14
  - Nanodevice, 73
    - designing in medicine, 6
  - Nanomaterials, 2, 3
    - for medicine, 3
    - Si based, 52
  - Nanomedicine, 3, 81
    - cancer therapy, 3
    - diverse scientific fields, 4
    - nanostructures in, 3
  - Nanometric scale, 2
  - Nanoparticle systems, 3
  - Nanoparticles, 5, 6
    - as targeting agents, 6
    - liquid crystal, 5
    - negatively charged, 60
    - neutral, 12
    - polymeric, 4
    - silica radio labeled, 65
    - solid silica, 34–36
    - with folic acid, 7
  - Nanoscale, 2, 3
  - Nanoscience, 1, 3
  - Nano-sized silica, toxicity of, 72
  - Nanospheres, 4
  - Nanostructures, 3, 5
    - for drug delivery, 5
  - Nanosystem
    - for drug delivery, 60
  - Nanosystems, 9
    - based on magnetite and silica, 53
    - pharmacokinetics analysis, 63

Nanotechnology, 1, 2  
 applied to medicine, 81  
 in biomedicine, 2

Nanotubes, 6

Natural polymer, 19

Near IR photoacoustic, 81

Near IR spectral region (NIR), 81

Negatively charged nanoparticles, 60

Neutral nanoparticles, 12

NIR sensitive dye, 82

Non-aqueous routes, 13

Nonporous Stöber nanoparticles, 74

Nutritional food pyramid, 30

**O**

Oleic acid, 14

Oncological diseases, 54–55

Oral insulin bioavailability, 56

Oral toxicity, Si, 29

Organic-inorganic hybrid materials, 31

**P**

Passive targeting, 7

Passive targeting strategy, 51

Pharmacokinetics, Si, 59–65

Phospholipids, 5

Photofrin®, 82

Photosensitizers (PS), 82

Phototherapy, 82

Physical adsorption, 82

Poly(ethylene glycol) (PEG), 62

Poly(*N*-vinyl pyrrolidone) (PVP), 14

Polymeric nanoparticles, 4

Polymers, 4, 19

Polyol method, 15

Polysaccharides, 19

Positively charged silica nanoparticles, 75

Protein  
 iron containing and oxygen transport, 81

Protein corona, 60, 61  
 formation of, 60, 61  
 macrophages recognize, 62

Proteins, 72

Pulmonary disease, 71

**Q**

Quantum dots, 6

Quartz, 27

**R**

Radioactive silica nanoparticles, 63

Reactive oxygen species (ROS), 73, 76

Reactive oxygen species (ROS), 72

Reticuloendothelial system, 6, 12, 64

Reticuloendothelial system, 63

Reticuloendothelial system, 6

Rhodamine B isothiocyanate (RITC), 67, 77

RuBPY dye, 62

**S**

Santa Barbara Amorphous (SBA-15), 32

Saos-2 cells, 52

Scanning tunneling microscope (STM), 2

Semiconductor nanocrystals, 6

Serum-free conditions, 61

Shell-core, 21

Short hairpin RNA (shRNA), 56

Si@MAG NPs, 40

Silanol groups, 32, 74

Silica, 7

Silica (Si), 31–34  
 as magnetic iron oxides coating, 39  
 based nanomaterials, 52  
 biological features of, 29  
 generalities of, 27–28  
 nanodevices containing, 56  
 naturally occurring, 28  
 solid silica nanoparticles, 34–36  
 water soluble forms of, 28  
 with importance in biomedicine, 31–34  
 bioglasses, 31–34  
 mesoporous silica (*see* Mesoporous silica)  
 star gels, 31

Silica coated magnetic nanoparticles, 45

Silica magnetic nanoparticles, 67

Silica nanoparticles, 6, 81  
 biodistribution of, 60, 62  
 distributed to liver, spleen, and lung, 64  
 elimination of, 64  
 in absence of proteins, 61  
 macrophages, 62  
 magnetic, 67–68  
 modified-solid, 64  
 naked solid, 63  
 on cellular toxicity, 74  
 PEG coated, 62  
 PEG modified, 62  
 radioactive, 63

- tissue distribution, 62
  - types of, 65
  - with plasma, 61
  - Silica-coated magnetic nanoparticles (MNPs), 39
    - methods to assess, 43
    - microemulsion method, 42–44
    - miscellaneous methods, 45–46
    - sodium silicate hydrolysis methods, 44–45
    - sonochemical deposition method, 45
    - Stöber process, 40–42
  - Silica-coated superparamagnetic iron oxide NPs, 54
  - Silicatein, 27
  - Siliceous sponges, 27
  - Silicic acid ( $\text{Si}(\text{OH})_4$ ), 28
    - with anions, 28
  - Silicon, 29
    - bioavailability and absorption of, 30
    - diet and, 29–30
    - in human body and signs of deficiency, 29
  - Silicon dioxide ( $\text{SiO}_2$ ), 27
    - crystalline forms of, 27
  - Silicosis, 71
  - Single domain particles, 12
  - Small interfering RNA (siRNA), 55
  - Sodium silicate hydrolysis, 45
  - Sodium silicate hydrolysis methods, 44–45
  - Sol-gel approaches, 46
  - Sol-gel process, 15
  - Solid silica nanoparticles, 34–36, 75
    - applications in medicine, 35
  - Solvothermal method, 17
  - Solvothermal synthesis, 15
  - Sonochemical deposition method, 45
  - Sonolysis/sonochemical method, 16
  - Splenocytes, 73
  - Spray aerosol technologies, 17
  - Spray pyrolysis, 17
  - Star gels, 31
  - Stimuli-responsive controlled drug delivery systems, 32, 34
  - Stöber process, 40–42, 63
    - advantages and disadvantages of, 41
    - to achieve Si@MAG, 42
  - Subnuclear pathology, 72
  - Superparamagnetic iron oxide nanoparticles, 12
  - Superparamagnetic iron oxides nanoparticles, 81
  - Superparamagnetism, 21
  - Sustained drug delivery systems (SDDSs), 32
  - Synthetic compounds, Si, 28
  - Synthetic polymer, 19
- T**
- Targeted drug delivery systems, 33, 51
  - Targeting agents, nanoparticles, 6
  - TEOS, 46
  - Tetraethyl orthosilicate (TEOS), 40
  - Tetraethylthosilicate (TEOS), 34
  - Tetravalent metalloid, 27
  - Theranostics, 53, 54, 81
  - Thermal decomposition, 17
  - Titania nanotubes, 6
  - Toxicologic assay, 74
  - Toxicology of silica, 29
  - Transition metal, 56
  - Transmembrane transporter, 66
  - Trifunctional device, 82
  - Triton X, 43
  - Tumoral therapeutic agent, 54
- U**
- Ultrasound, 45
  - Ultrasound irradiation, 16
  - US Food and Drug Administration (FDA), 56
- Y**
- Yolk structure, 21